DaVita Inc.

DaVita Inc.

DVA

$182.20

Updated: 03/11/2026, 22:10:59

Market Cap
$11.46B
Sector
Healthcare
Industry
Medical - Care Facilities
Country
US

No historical data available

Company Profile

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

USD
NYSE
CEO: Javier J. Rodriguez
Employees: 78,000
https://www.davita.com
Asset Summaries
Latest generated summaries for DVA

No summaries found.

Detailed business
Evidence-backed facts extracted from the latest official annual filing.
DVA-10-k-fy2025.html2.9 MBtext/htmlENFiled 11/02/2026Period ended 31/12/2025

Business monitoring

Reported and calculated KPIs plus operational exposure disclosed in the FY 2025 filing.

Evidence-backed · 38 KPI observations

Revenue

N/A

FY — · Reported

Net income

$0.7B

FY 2025 · Reported

Gross margin

N/A

FY — · Reported

Free cash flow

$1.3B

FY 2025 · Calculated

R&D intensity

N/A

FY — · Reported

Share repurchases

$1.3B

FY 2025 · Reported

Earnings and cash generation
USD billions, directly sourced from inline XBRL; free cash flow is operating cash flow less capex.
Profitability and reinvestment
Margins and R&D as a percentage of revenue.
Geographic footprint
What the filing identifies, separated by location role so partner manufacturing is not presented as Apple-owned factories.
1 named headquarters
0 manufacturing countries
0 individually named factories

Map layer

Pins show disclosed operations. The heatmap colors the filing’s reported geographies; regional figures shade the region and are not estimates for each country.

No reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosureNo reported geographic revenue disclosure
Named headquarters Manufacturing partner country

Only locations and quantities explicitly supported by the filing are displayed. A country-level manufacturing percentage or product allocation is shown only when the source discloses it; materiality scores are never presented as production shares.

How the business makes money

Principal business

Provider of dialysis and related lab services in the U.S. (leading provider for ESRD/ESKD patients), plus IKC, ancillary services, and international operations

98%
Source evidence
“Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business.”

U.S. dialysis industry competition landscape

Competition from large/medium providers, new entrants, private equity-backed kidney care providers, nephrologists, and non-traditional entrants across kidney care continuum

95%
Source evidence
“we also compete with new dialysis providers, private equity-backed kidney care providers, individual nephrologists and former medical directors or physicians that have opened their own dialysis units or facilities.”

Operations and dependencies

Reliance on third-party suppliers and vendors

Reliance on significant suppliers for pharmaceuticals and critical clinical products; supply chain and tariff risks including home dialysis services

92%
Source evidence
“our reliance on significant suppliers, service providers and other third party vendors to provide key support to our business operations ... including, among others, suppliers of certain pharmaceuticals, administrative or other services or critical clinical products”

Positioning and strategy

Largest competitor Fresenius Medical Care with vertical integration cost advantage

Fresenius Medical Care is DaVita's largest competitor and also manufactures its own supplies and equipment, which may provide cost advantages

98%
Source evidence
“Some competitors, including our largest competitor, Fresenius Medical Care, also manufacture their own supplies and equipment, in addition to owning and operating outpatient dialysis centers worldwide, which may, among other things, provide cost advantages to such competitors.”

ESKD/CKD population growth drivers and mortality risks

Treatment volumes driven by aging/growth of U.S. population, immigration, transplant availability, diabetes/hypertension incidence; elevated mortality from flu/COVID-19 and vaccine hesitancy negatively impacted treatment volume

94%
Source evidence
“severe flu seasons and the ongoing incidence of other infectious diseases such as COVID-19 in recent years have driven elevated mortality in our patient population, which has in turn had a negative impact on treatment volume. The negative perception of vaccinations in the U.S. has exacerbated these risks.”

Integrated Kidney Care (IKC) value-based care investment

IKC/VBC business: assumes total-patient-cost accountability; success depends on reducing cost of care and actuarially sound payor agreements; significant CKCC investments

90%
Source evidence
“Because we assume financial accountability for total patient cost in these IKC and VBC arrangements, we are exposed to the risk that the funding and financial terms of these arrangements may not be sufficient to cover our expenses”

Home-based dialysis modality growth

Home hemodialysis and PD are an important part of overall strategy with investment in processes and infrastructure; risks include supplier availability and market entry by competitors

90%
Source evidence
“There are also a limited number of available suppliers for certain critical home-based dialysis supplies, and any disruptions involving such supplies could materially impact our operations”

Risks, financing, and outlook

Rising labor costs and clinical workforce shortage

Labor-intensive business; wage pressure, skilled clinical labor shortages (nurses, NPs) may increase costs faster than reimbursement

95%
Source evidence
“we face increasing labor costs generally, including through elevated compensation levels to our teammates, and we continue to face increased labor costs and difficulties in hiring skilled clinical personnel, including nurses, due to nationwide shortages”

Inflation, labor market, and supply chain pressures on cost structure

Inflation, labor supply shortages, supply chain pressures increase staffing, labor, and supply costs; may outpace Medicare rate increases

95%
Source evidence
“We expect that certain of those increased costs will persist in the near term as inflationary and supply chain pressures and challenging labor market conditions continue.”

2025 financing transactions

New TLA-2 ($2,000M), revolver (up to $1,500M), TLB-2 ($1,878M); repaid TLA-1/TLB-1; issued $1,000M 6.75% senior notes due 2033

96%
Source evidence
“entry into a new Term Loan A-2 facility in the aggregate principal amount of $2,000 million and a revolving line of credit in an aggregate principal amount up to $1,500 million”

Interest rate hedging and leverage target

Purchased $4,750M notional forward interest rate caps through 2029; leverage ratio within 3.0x–3.5x target throughout 2025

95%
Source evidence
“we purchased an additional $4,750 million notional amount of forward interest rate caps to shield our exposure to significant interest rate increases through 2029”

2026 U.S. dialysis treatment volume expectation

Approximately flat U.S. dialysis treatment volumes expected in 2026

95%
Source evidence
“In 2026 in our U.S. dialysis business, we expect approximately flat treatment volumes due to the net impact of a number of factors.”

2025 share repurchases

Repurchased 12,678,623 shares for $1,788M; 14.9% net reduction in outstanding share count YoY

96%
Source evidence
“repurchase of 12,678,623 shares of our common stock for aggregate consideration of $1,788 million, and a 14.9% net reduction in our outstanding share count year-over-year”

2025 cybersecurity incident

Company experienced a cybersecurity incident in 2025, cited as a risk to billing/collections and information systems

93%
Source evidence
“any extended billing or collections cycles including, without limitation, due to defects or operational issues in our billing systems, the impact of the cybersecurity incident experienced by the Company in 2025”

State dialysis payment initiatives including California AB 290 charitable premium assistance reimbursement cap

State initiatives to limit dialysis payments; CA AB 290 reimbursement cap stayed pending appeal

95%
Source evidence
“in October 2019, a California bill (AB 290) was signed into law that limits the amount of reimbursement paid to certain providers for services provided to patients with commercial insurance who receive charitable premium assistance (reimbursement cap). The implementation of AB 290 has been stayed pending resolution of legal challenges.”

Labor-intensive business with labor cost, retention, and union organizing risk

Business is labor intensive; risk of labor cost increases, talent retention, and union organizing

97%
Source evidence
“our business is labor intensive and we may experience increases in labor costs, our ability to attract and retain key leadership talent or employees, or union organizing activities”

Reliance on commercial insurance mix and private payor contracting

Revenue depends on percentage of higher-paying commercial patients and private payor contract terms

97%
Source evidence
“the number or percentage of patients with higher-paying commercial insurance and our ability to negotiate and maintain contracts with private payors on competitive terms”

Government healthcare program participation risk

Participation in Medicare, Medicare Advantage, Medicaid and Department of Veterans Affairs programs is a principal risk

96%
Source evidence
“our participation in government healthcare programs, including Medicare, Medicare Advantage, Medicaid and the Department of Veterans Affairs”

Severe weather and natural disaster exposure including Florida clinical laboratory

Severe weather/natural disasters threaten facilities and suppliers; clinical laboratory located in Florida (hurricane-prone)

95%
Source evidence
“For example, our clinical laboratory is in Florida, a state that has in the past experienced and may in the future experience hurricanes.”

Medicare ESRD PPS bundled payment risk

Dialysis reimbursement via ESRD PPS bundle subject to rate adjustments; a material reduction in reimbursement could have a material adverse effect

95%
Source evidence
“Rates and bundled payments under the ESRD PPS are subject to adjustment from time to time based on a number of factors and may not cover our costs thereby having an adverse impact on our revenues.”

Supplier and third-party service provider dependency risk

Risk around cost-effective supplier relationships, access to technology, and growing reliance on third-party service providers

95%
Source evidence
“our ability to establish and maintain supplier and service provider relationships that meet our needs at cost-effective prices or at prices that allow for adequate reimbursement as applicable, our ability to access new technology or superior products in a cost-effective manner and our increasing reliance on third party service providers”

Commercial payor concentration and rate pressure

Concentration of profits from higher-paying commercial plans with continued downward pressure on average realized payment rates

94%
Source evidence
“the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates”

Debt covenant compliance and indebtedness risk

Risk related to level of indebtedness, cash generation for debt service, and debt covenant compliance

94%
Source evidence
“our current or future level of indebtedness, including, without limitation, our ability to generate cash to service our indebtedness and for other intended purposes and our ability to maintain compliance with debt covenants”

Government policy and regulatory risks (OBBBA, Medicare/Medicaid)

Exposure to OBBBA, government shutdowns, and Medicare/Medicaid/MA reimbursement rate changes

93%
Source evidence
“a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure and adjustment methodologies”

Labor market and clinical workforce shortage

Challenging, highly competitive labor market with nationwide shortage of skilled clinical personnel; elevated turnover and labor costs

92%
Source evidence
“the current challenging and highly competitive labor market conditions, including due to the ongoing nationwide shortage of skilled clinical personnel”

VA National Dialysis Service Contract dependency

VA NDSC since 2013 with Medicare PPS-linked pricing; VA has right to terminate without cause on short notice; non-renewal could force center closures or lower reimbursement

90%
Source evidence
“our current agreement with the VA provides the VA with the right to terminate the contract without cause on short notice”

Medicaid OBBBA phase-down and eligibility risk

OBBBA federal Medicaid expenditure phase-down: work requirements, higher cost-sharing, provider tax limits could reduce patient volumes and revenue

90%
Source evidence
“these eligibility requirements are part of an overarching phase down of federal Medicaid expenditures in the OBBBA, along with provisions such as higher cost-sharing for certain patients and limitations on state funding mechanisms, known as provider taxes and state-directed payments”

Medicare Advantage contracting risk

MA plan risks: CMS rate/risk-adjustment changes pressuring negotiated rates; MA non-compliance could trigger plan terminations and enforcement

90%
Source evidence
“the risk that CMS sets annual reimbursement rates or modifies risk adjustment methodologies for MA plans that in turn lead commercial payors to seek to reduce their negotiated rates with us and/or fund us less for services rendered”

Cybersecurity and PHI/data integrity risk

Systems hold sensitive PHI, SSNs and credit card data; vulnerability to security breaches including state-sponsored cyberattacks could materially harm operations

90%
Source evidence
“including sensitive personal information, such as PHI, social security numbers, and/or credit card information of our patients, teammates, physicians, business partners and others”

International expansion exposure

International expansion and non-U.S. third-party suppliers expose company to political, economic, currency, tariff, FCPA and privacy risks

85%
Source evidence
“We are continuing to expand our operations by offering our services and entering new lines of business in certain markets outside of the U.S., and as a result have increased our utilization of third-party suppliers and service providers operating outside of the U.S.”

CMS data reporting and payment integrity risk

Risk of inaccurate data reporting to CMS causing overpayments, liabilities, penalties, and reputational harm; commercial insurers may adopt similar limitations

85%
Source evidence
“failures in our clinical and operational processes or systems could lead to inaccurate data reporting to CMS or other data integrity issues with respect to the reported information, potentially resulting in overpayment and potential associated liabilities, penalties, and reputational harm”

Material exposure graph

Commercial insurance payors
Revenue Exposure

Profits are concentrated in higher-paying commercial payor plans; rate pressure, plan design changes, and policy shifts (e.g., charitable premium assistance restrictions) directly affect revenue and profitability.

Relevance 95·Dependency 90·Confidence 94
Source evidence
“the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates”
Medicare ESRD Prospective Payment System
Regulatory Exposure

Core dialysis revenue is set by the ESRD PPS bundle; rate adjustments or inadequate funding of bundle components directly affect revenues.

Relevance 95·Dependency 90·Confidence 95
Source evidence
“Any failure to adequately calculate or fund the costs associated with these items or a material reduction in reimbursement under the ESRD PPS could have a material adverse effect on our business, results of operations, financial condition and cash flows.”
Commercial payors
Revenue Exposure

Revenue materially depends on the share of higher-paying commercially insured patients and on negotiating/maintaining competitive private payor contracts.

Relevance 95·Dependency 80·Confidence 95
Source evidence
“the number or percentage of patients with higher-paying commercial insurance and our ability to negotiate and maintain contracts with private payors on competitive terms”
U.S. government healthcare programs (Medicare, Medicare Advantage, Medicaid, VA)
Revenue Exposure

Participation in Medicare, Medicare Advantage, Medicaid, and VA programs is a principal revenue-related risk; costs may increase faster than Medicare rate updates.

Relevance 95·Dependency 80·Confidence 95
Source evidence
“our participation in government healthcare programs, including Medicare, Medicare Advantage, Medicaid and the Department of Veterans Affairs”
Labor shortages and challenging labor market conditions
Cost Driver

Labor-intensive dialysis operations face cost pressure from labor supply shortages and challenging labor market conditions, plus competition for skilled clinical personnel.

Relevance 90·Dependency 75·Confidence 94
Source evidence
“labor supply shortages and other challenging labor market conditions have continued to put pressure on our existing cost structure, including among other things, staffing, labor and supply costs.”
Clinical labor shortage and wage inflation
Cost Driver

Nationwide nursing shortages and wage pressure raise labor costs that may outpace Medicare rate increases and limit expansion of IKC and kidney care services.

Relevance 90·Dependency 75·Confidence 95
Source evidence
“the ongoing nursing shortage may limit our ability to expand our operations”
ESKD/CKD population growth and demographic trends
Demand Driver

Treatment volumes and revenues depend on ESKD/CKD population growth driven by aging, immigration, diabetes/hypertension incidence, and transplant availability; elevated mortality reduces treatment volumes.

Relevance 90·Dependency 70·Confidence 93
Source evidence
“the growth and aging of the U.S. population, changing U.S. immigration levels, the availability of transplant opportunities, incidence rates for diseases that cause kidney failure such as diabetes and hypertension, or growth rates of minority populations with higher-than-average incidence rates of ESKD”
Pharmaceuticals
Supplier Dependency

DaVita depends on significant suppliers for pharmaceuticals and critical clinical products; vendor disruption or tariff-driven cost increases would impair operations including home dialysis.

Relevance 85·Dependency 80·Confidence 92
Source evidence
“suppliers of certain pharmaceuticals, administrative or other services or critical clinical products”
Clinical labor shortage
Cost Driver

Nationwide shortage of skilled clinical personnel drives elevated turnover, contract labor use, and labor cost increases.

Relevance 85·Dependency 70·Confidence 92
Source evidence
“the ongoing nationwide shortage of skilled clinical personnel”
Fresenius Medical Care
Competitive Exposure

Fresenius, DaVita's largest competitor, manufactures its own dialysis supplies and equipment, potentially giving it cost advantages over DaVita.

Relevance 85·Dependency 60·Confidence 97
Source evidence
“Some competitors, including our largest competitor, Fresenius Medical Care, also manufacture their own supplies and equipment, in addition to owning and operating outpatient dialysis centers worldwide, which may, among other things, provide cost advantages to such competitors.”
One Big Beautiful Bill Act (OBBBA) Medicaid provisions
Revenue Exposure

OBBBA work requirements, cost-sharing, and provider tax limitations could reduce Medicaid patient volumes and payments for dialysis services.

Relevance 85·Dependency 60·Confidence 90
Source evidence
“If these and other changes result in decreased patient volumes and revenue, substantially reduced Medicaid payments... it could have a material adverse impact on our business, results of operations, financial condition and/or cash flows.”
Information systems and billing infrastructure
Technology Dependency

Reliance on internal and third-party information systems and billing services; the 2025 cybersecurity incident illustrates breach and billing-cycle risk.

Relevance 80·Dependency 75·Confidence 90
Source evidence
“our ability to successfully maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely”
Supplier and third-party service provider reliance
Supplier Dependency

DaVita depends on supplier/service provider relationships at cost-effective prices, access to pharmaceuticals/devices technology, and increasingly on third-party service providers; severe weather can strain supply chains.

Relevance 80·Dependency 70·Confidence 92
Source evidence
“Severe weather events or natural disasters could also strain global supply chains to the extent such events result in equipment and clinical supply shortages, disruptions, delays or associated price increases.”
Cybersecurity and data privacy
Regulatory Exposure

Operations depend on secure processing of PHI and other sensitive data, including reliance on critical IT vendors; breaches including state-sponsored attacks could materially harm the business.

Relevance 80·Dependency 65·Confidence 90
Source evidence
“coordinated attacks by a variety of actors, including, among others, activist entities or state sponsored cyberattacks”
Integrated Kidney Care / value-based care
Demand Driver

IKC/VBC growth strategy depends on actuarially sound payor contracts, CMMI/CKCC model continuation, and reducing total cost of care; company bears total-cost financial accountability.

Relevance 80·Dependency 50·Confidence 90
Source evidence
“we have made significant investments in our participation in the CKCC program payment model and there is no assurance that this program will be extended or modified in the future”
Patient mortality and admissions trends
Demand Driver

Elevated mortality relative to pre-pandemic periods and admissions levels drive treatment volume, expected approximately flat in 2026.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“mortality levels that remain elevated relative to pre-pandemic periods, but assuming a slight improvement in flu impact compared to 2025”
Home-based dialysis (home hemodialysis and peritoneal dialysis)
Supplier Dependency

Home dialysis growth strategy is exposed to limited supplier availability for critical supplies and evolving market competition with relative ease of entry.

Relevance 75·Dependency 60·Confidence 90
Source evidence
“This developing market may create additional opportunities for competition with relative ease of entry”
U.S. Department of Veterans Affairs
Customer Exposure

Dialysis services provided to VA under NDSC with Medicare PPS-linked pricing and short-notice termination right; loss could force center closures.

Relevance 75·Dependency 55·Confidence 90
Source evidence
“Should the VA not renew or cancel our current contract for any reason... we may be required to cease accepting patients under this program and may be forced to close centers or experience lower reimbursement rates”
California AB 290 (charitable premium assistance reimbursement cap)
Regulatory Exposure

AB 290 would cap reimbursement for commercially insured patients receiving charitable premium assistance; implementation stayed pending appeal, but passage of similar state initiatives could materially harm results.

Relevance 70·Dependency 55·Confidence 92
Source evidence
“There have been several state-based policy initiatives to limit payments to dialysis providers or impose other burdensome operational requirements, which, if passed, could have a material adverse impact on our business, results of operation, financial condition and cash flows.”
Trade policies and tariffs
Cost Driver

Evolving trade policies and tariffs may increase cost of supplies and disrupt availability of clinical supplies, including for home dialysis.

Relevance 65·Dependency 55·Confidence 88
Source evidence
“the impact of evolving trade policies and tariffs and any reduction in clinical and other supplies due to any disruptions experienced by third party vendors”
Full company information
Latest profile, trading, valuation, and identifier data stored for DVA.
Share price
$182.20
Market cap
$11.46B
Exchange
NYSE
Currency
USD
CEO
Javier J. Rodriguez
Employees
78,000
IPO date
31/10/1995
Beta
0.795
Last dividend
$0.00
Day range
$180.05 – $184.57
52-week range
$101.00 – $247.49
1-day performance
-1.91%
1-year performance
80.40%
Current drawdown (1Y)
-26.38%
CIK
0000927066
CUSIP
23918K108
ISIN
US23918K1088
Created
07/12/2025, 03:41:00
Last update
03/11/2026, 22:10:59

Track DaVita Inc. with an AI analyst

See which prediction-market events move DVA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.